| |NOVEMBER 20249BAYER & DEWPOINT THERAPEUTICS INK PACT FOR HEART DISEASE PROGRAMMATICA BIOTECH & KALIVIR INK LOI FOR ONCOLYTIC VIRAL IMMUNOTHERAPY TIESBayer has made an exclusive deal with Dewpoint Therapeutics, Inc. for a heart disease program targeting dilated cardiomyopathy (DCM) patients with specific mutations. This marks the initial opportunity for collaboration between Bayer and Dewpoint Therapeutics, Inc., initiated in November 2019. It combines Dewpoint's unique biomolecular condensates platform with Bayer's expertise in small molecule drug development to create innovative therapies for cardiovascular and renal illnesses."One of the biggest challenges in drug discovery lies in tackling the undruggable human proteome," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's Pharmaceuticals Division. "The emerging paradigm of biomolecular condensates is expanding the traditional drug target space for small molecules by unveiling new targets and new approaches to previously intractable targets. We are excited to be part of this new wave of innovation together with Dewpoint Therapeutics as it is our ambition to provide transformative medicines to cardiovascular patients with the highest unmet needs."Dilated cardiomyopathy (DCM) is a condition affecting the heart muscle in which the ventricles become enlarged and have difficulty efficiently pumping blood. The authorized program is centered on a new approach to tackle a particular type of DCM connected to mutations that result in the creation of condensates associated with the disease. This type of DCM is a serious condition with substantial medical needs that are not being met, marked by heart failure beginning at a young age and frequent dangerous irregular heartbeats. POMatica Biotechnology Inc. (Matica Bio), a company specializing in viral vector development and manufacturing, has revealed the signing of a Letter of Intent (LOI) with KaliVir Immunotherapeutics, a clinical-stage biotechnology company from the U.S. working on advanced, multi-mechanistic oncolytic viral immunotherapies.KaliVir is leading the way in creating new cancer treatments with their exclusive Vaccinia Enhanced Template (VETTM) platform. This platform enables the expression and systematic delivery of numerous therapeutic transgenes. The primary clinical candidate of KaliVir, VET3-TGI, produces interleukin-12 and a TGFbeta inhibitor.In this new collaboration, Matica Bio will use their exclusive cell line, MatiMaxTM, to investigate a different production method for KaliVir's oncolytic virus product.Helena Chaye, CEO of KaliVir, stated, "Our collaboration with Matica Bio allows us to accelerate the development of our oncolytic virus therapies. This agreement is expected to expand our strategic partnership across all phases of product development.""The development of production processes for viral vectors is crucial for the stable production of high-quality therapeutics. Through this agreement, we aim to leverage our high-performance MatiMaxTM cell line and CGT manufacturing expertise to actively support KaliVir's oncolytic virus program," said Paul Kim, CEO of Matica Bio.Matica Biotechnology is a CDMO specializing in viral vector manufacturing that utilizes cutting-edge technologies at its dedicated cGMP facility. PO
< Page 8 | Page 10 >